Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Dale Baker who wrote (2150)	7/14/1999 1:15:00 PM
From: Mike M	Read Replies (2) \| Respond to of 10293

If the product is that good and everyone knows it - you guys have brought out a lot of info - then I think you would see GUMM trade a lot higher. That's assuming this product is more than a one-season flop. Yes, all is predicated on the product working. It is interesting that VPHM which promises far less of a cold remedy and has over 11M shares outstanding is trading up to 19 today... The key is in your first line "and everyone knows it"...thus far it is hardly well publicized. Much does depend on the NEJM acceptance of the data and publication. The problem, of course, is that if it comes out with an endorsement the price will no longer be $12... Some of us just have faith....